Ignite Creation Date:
2024-05-06 @ 3:55 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04803370
Status:
COMPLETED
Last Update Posted:
2024-04-26
First Post:
2021-03-09
Brief Title:
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
Sponsor:
Hospital Son Llatzer
Organization:
Hospital Son Llatzer
Study Overview
Official Title:
Study of the Efficacy of Reinforcing of the Standard Therapy in COVID-19 Patients With Repeated Transfusion of Immune Plasma From COVID-19 Convalescents vs Exclusive Standard Therapy in Hospitalized COVID-19 Patients
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The coronavirus disease 2019 COVID-19 was classified as a pandemic by the World Health Organization WHO in March 2020 The SARS-COV-2 virus is easily transmissible and there is currently no approved treatment with effective results Although the main epidemiological parameters are currently being studied apparently the speed of contagion the incidence and the mortality rate in severe cases appear to be high Therefore there is an urgent need to find a viable therapeutic option The present trial is a pilot study with an objective to determine the efficacy of standard treatment reinforced with two repeated doses in two consecutive days of plasma from former convalescent people of the COVID-19 disease already discharged and or with results in negative COVID-19 screenings transfused to hospitalized COVID-19 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None